For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Cambridge Neuroscience, Inc.

USPTO Granted Patents = 43

EPO Patents = 1

Forward Citations = 491

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Lain-Yen Hu (23 out of 25 patents)

Stanley M Goldin (21 out of 24 patents)

James B Fischer (19 out of 21 patents)

4. N Laxma Reddy (19 out of 24 patents)

5. Andrew Gannett Knapp (18 out of 21 patents)

6. Subbarao Katragadda (18 out of 20 patents)

7. Lee David Margolin (16 out of 16 patents)

8. Graham J Durant (15 out of 29 patents)

9. Sharad S Magar (13 out of 18 patents)

10. Andrew David Goodearl (7 out of 20 patents)

11. Luisa Minghetti (7 out of 19 patents)

12. Paul Stroobant (7 out of 20 patents)

13. Michael Derek Waterfield (7 out of 31 patents)

14. Ian D Hiles (7 out of 24 patents)

15. Mark Marchioni (6 out of 15 patents)

Core Competencies:

Therapeutic Guanidines

Pharmaceutically Active Compounds

Glial Mitogenic Factors

Eye Trauma Treatment

Cellular Communication Modulators

Sigma Receptor Ligands

Substituted Aminoguanidines

Hydrazinedicarboximidamide Compounds

Calcium Channel Antagonists

Antibody Preparation

Fucosylated Guanosine Disulfates

43 patents: Sort by Forward Citations

1. 6787569 - Therapeutic guanidines (2004-09-07),

2. 6774263 - Pharmaceutically active compound and methods of use (2004-08-10),

3. 6756389 - Pharmaceutically active compounds and methods of use (2004-06-29),

4. 6242198 - Methods of treatment of eye trauma and disorders (2001-06-05),

5. 6232061 - Homology cloning (2001-05-15),

6. 6174924 - Therapeutic guanidines (2001-01-16),

7. 6156741 - Therapeutic substituted guanidines (2000-12-05),

8. 6153604 - Therapeutic substituted guanidines (2000-11-28),

9. 6147190 - Glial mitogenic factors, their preparation and use (2000-11-14),

10. 6147063 - Therapeutic substituted guanidines (2000-11-14),

11. 6143791 - Therapeutic guanidines (2000-11-07),

12. 6087346 - Sigma receptor ligands and the use thereof (2000-07-11),

13. 6087323 - Use of neuregulins as modulators of cellular communication (2000-07-11),

14. 6071969 - Substituted aminoguanidines and methods of use thereof (2000-06-06),

15. 6025355 - Pharmaceutically active compounds and methods of use (2000-02-15),

Company Overview

Cambridge Neuroscience, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative therapeutic solutions. The organization focuses on a range of advanced pharmacological compounds, including therapeutic guanidines and sigma receptor ligands, aimed at addressing neurological disorders. Their research encompasses glial mitogenic factors and calcium channel antagonists, contributing to the understanding and treatment of complex neurobiological conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

43 Patents

#67 in Cambridge, MA

#467 in Massachusetts

#8,099 in US

#16,040 in the World

Cambridge, MA, United States of America

Cambridge Neuroscience, Inc.

Forward Citations = 491

40 inventors:

Lain-Yen Hu (23 out of 25 patents)

Stanley M Goldin (21 out of 24 patents)

James B Fischer (19 out of 21 patents)

4. N Laxma Reddy (19 out of 24 patents)

5. Andrew Gannett Knapp (18 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cambridge Neuroscience, Inc.. Retrieved from https://idiyas.com/company/cambridge-neuroscience

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…